Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
WALTHAM, Mass., May 30, 2017 -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2017 Global Healthcare Conference on June 6, 2017 at 11:00 a.m. Eastern Time.
The presentation will be webcast and accessible through the investor relations section of the Company’s web site, http://ir.minervaneurosciences.com.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva’s proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); MIN-202 (JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376
